Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
February 2005
Features
Letter to the Editor
Act Now: Raising Awareness of DVT
Efforts are under way to educate health care professionals and the public about deep vein thrombosis, a common, potentially fatal disease.
James Groce III, PharmD, CACP
A Pharmacoeconomic Model for Making Value-Based Decisions About Serotonin Reuptake Inhibitors
The authors discuss formulary considerations for the largest therapeutic class of prescription drugs and their efficacy in treating depression and anxiety.
Patrick W. Sullivan, PhD; Robert Valuck, PhD, RPh; Diana I. Brixner, PhD; Edward P. Armstrong, PharmD
Meeting Highlights
46th Annual Meeting of the American Society of Hematology
Dr. Prescott reviews the latest developments in treatments for malignant and nonmalignant hematological diseases.
Lawrence M. Prescott, PhD
Continuing Education Credit
An Evidence-Based Summary of Insulin Analogues
The authors compare and contrast the safety and efficacy of the newer insulin products—insulin aspart (NovoLog®), lispro (Humalog®), and glargine
(Lantus®)—with existing human insulin (e.g., Humulin®, Novolin®).
Bethany A. Fedutes, PharmD, Amy Calabrese Donihi, PharmD, BCPS, Colleen M. Culley, PharmD, BCPS, Bryan J. McCreery, PharmD Candidate, and Nicole T. Ansani, PharmD
Departments
Editorial
Who Will Choose Your Medications?
David Nash, MD, MBA, discusses the possibility of limited choices of medications for physicians and the public under the new Medicare drug benefit.
David B. Nash, MD, MBA
Prescription: Washington
Congress Whets Its Carving Knife: Deep Cuts for Medicaid Drug Reimbursement
Stephen Barlas anticipates the likelihood of decreased Medicaid reimbursement to pharmacies for prescription drugs.
Stephen Barlas
Medication Errors
Admitting “Overflow” Patients to Units Without Proper Expertise Invites Errors
Matthew Grissinger, RPh, FASCP, discusses the risk of errors when staff members are not adequately informed about the potential dangers of glycoprotein IIb/IIIa inhibitors.
Matthew Grissinger, RPh, FASCP
New Drugs/Drug News/New Medical Devices
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
Ximelagatran (Exanta™): A Product Review and Update
Drs. Hilas and Marzella review ximelagatran (Exanta™), an oral direct thrombin inhibitor.
Olga Hilas, BS, PharmD, and Nino Marzella, BS, PharmD
